PrecisionPhage Announces the Global Phage Therapy Bridge 2027 in Singapore
Phage therapy is advancing rapidly, yet development remains fragmented across regions and ecosystems. The Global Phage Therapy Bridge was created to connect these capabilities by linking clinical practice, scientific discovery, regulatory pathways, manufacturing readiness, technology platforms, and commercial strategy across Europe, the UK, North America, and Asia-Pacific. Over two days in Singapore we will discuss real world clinical experience, emerging solutions, regulation, manufacturing and GMP, reimbursement, patient access, and opportunities for concrete international projects.
“Phage therapy is moving forward faster than ever, but the world is still working in silos,” said Matti Jalasvuori, CEO of PrecisionPhage. “This event brings together the people who can turn scientific promise into global therapeutic reality.”
With limited seats, the Global Phage Therapy Bridge offers one of 2027’s most exclusive opportunities to gain insights, form strategic collaborations, and influence the global trajectory of phage therapy.
Early registration is strongly recommended. Agenda highlights and registration details: Global Phage Therapy Bridge | Singapore 2027
